arrow
Y

Yasuhisa Fujii

Institute of Science Tokyo
H指数:53
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study

YUSHIMA研究:在经过铂类化疗和免疫检查点抑制剂治疗后的转移性尿路上皮癌患者中接受恩福妥单抗维多汀治疗的预后模型性能

2026-05-010
PRE
Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma

非转移性透明细胞肾细胞癌中KEYNOTE-564与AUA风险分层的比较预后性能

2026-01-010
PRE
Predictors of Survival and Recurrence After Partial or Radical Nephrectomy in Women with Localized Renal Cell Carcinoma: A Multicenter Analysis

局部肾细胞癌女性患者行部分或根治性肾切除术后的生存与复发预测因素:一项多中心分析

2026-01-010
PRE
Impact of Impaired Renal Function on the Efficacy and Safety of Enfortumab Vedotin Monotherapy in a Multicenter Real-World Cohort of Patients With Metastatic Urothelial Cancer: YUSHIMA Study

受损肾功能对恩福妥单抗单药疗法在转移性尿路上皮癌多中心真实世界队列中的有效性和安全性的影响:YUSHIMA 研究

2025-11-010
PRE
Association of Elevated Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and De Ritis Ratios With Major Complications After Surgery for Renal Cell Carcinoma: A Pathway to Optimize Charlson Comorbidity Index and Preoperative Predictive Modeling

升高的中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值以及De Ritis比值与肾细胞癌术后主要并发症的关联:优化Charlson合并症指数和术前预测模型的一条途径

2025-11-011
PRE
Proposed tripartite classification of T1 renal cell carcinoma: Comparison with current binary system

T1肾细胞癌的三元分类法提案:与当前二元系统的比较

2025-11-010
PRE
Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial

日本转移性激素敏感性前列腺癌患者中恩扎卢胺联合雄激素剥夺疗法的贝叶斯再分析:ARCHES试验中频率分析的补充方法论

2025-10-010
PRE
The Role of Salvage Cystectomy After Prior Trimodality Therapy: A Multinational Match-paired Analysis
2025-04-280
OAAI